Studing the effects of TRC105 (new drug) and bevacizumab on recurrent brain tumors

What we are studying

Subjects with recurrent brain tumors will be randomized to receive treatment with either TRC105 and bevacizumab or bevacizumab alone.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Previous treatment with radiation therapy or chemotherapy allowed

What is involved

  • Treatment with TRC105 and bevacizumab or bevacizumab alone

Compensation

None

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.